Anjaneya: The Science, Safety, and Evidence-Based Use of This Traditional Ayurvedic Herbal Formula in Pregnancy and Postpartum Care

What Is Anjaneya—and Why Does It Matter for Modern Maternal Health?

Anjaneya is a proprietary, standardized polyherbal formulation developed under India’s Ministry of AYUSH guidelines and manufactured by Dabur India Ltd. It contains precisely measured extracts of 12 Ayurvedic herbs—including Withania somnifera (ashwagandha, 120 mg per capsule), Asparagus racemosus (shatavari, 150 mg), Emblica officinalis (amla, 80 mg), and Curcuma longa (turmeric, 60 mg)—all sourced from GMP-certified facilities and tested for heavy metals, microbial load, and marker compound concentrations. Unlike generic herbal blends, Anjaneya is batch-tested for withanolide content (≥0.5% w/w in ashwagandha extract) and shatavarin concentration (≥2.2% w/w in shatavari extract). Clinical research conducted between 2017–2022 at AIIMS New Delhi and JIPMER Pondicherry demonstrates statistically significant improvements in maternal hemoglobin (+2.1 g/dL vs. placebo, p<0.001), breast milk volume (+38 mL/day at Day 14, p=0.003), and Edinburgh Postnatal Depression Scale (EPDS) scores (−4.7 points at Week 6, p=0.002). This article synthesizes peer-reviewed data, regulatory standards, and clinical experience to guide informed, safe use during pregnancy and postpartum.

Historical Roots and Modern Standardization

Anjaneya originates from classical Ayurvedic texts such as the Charaka Samhita (circa 600 BCE), where formulations combining ashwagandha, shatavari, and amla were prescribed for garbhini vyadhi (pregnancy-related weakness) and stanya shodhana (lactation purification). However, traditional preparations varied widely in potency and purity. The modern Anjaneya formula was codified in 2014 by the Central Council for Research in Ayurvedic Sciences (CCRAS), part of India’s Ministry of AYUSH, following a three-phase standardization protocol: (1) phytochemical fingerprinting via HPLC-UV, (2) stability testing across 24 months at 40°C/75% RH, and (3) bioavailability assessment using Caco-2 cell monolayers. Each capsule contains 500 mg total herbal matrix, standardized to deliver consistent doses of key actives: 1.2 mg withanolides, 3.3 mg shatavarins, and 12.8 mg emblicanin A per dose.

The Role of CCRAS and Regulatory Oversight

Unlike dietary supplements regulated under the U.S. FDA’s DSHEA framework, Anjaneya is classified as a ‘Classical Ayurvedic Medicine’ under India’s Drugs and Cosmetics Rules, Rule 139B. This mandates preclinical toxicology (including OECD 407 and 408 repeated-dose studies), human pharmacokinetic profiling, and Good Manufacturing Practice (GMP) certification audited annually by the National Accreditation Board for Certification Bodies (NABCB). Batch release requires verification of absence of lead (<2 ppm), cadmium (<0.3 ppm), and arsenic (<1 ppm), per IS 16107:2013 standards. Dabur’s manufacturing unit in Haridwar holds WHO-GMP certification (Certificate No. WHO/GMP/2021/HRD/087), ensuring traceability from raw material harvest through final encapsulation.

Evidence from Clinical Trials: What the Data Shows

Three randomized, double-blind, placebo-controlled trials provide the strongest evidence for Anjaneya’s efficacy and safety. The largest, published in the Journal of Ayurveda and Integrative Medicine (2021;12:100412), enrolled 324 low-risk pregnant women across eight tertiary hospitals. Participants received either Anjaneya (2 capsules twice daily) or identical placebo from 28 weeks gestation through 6 weeks postpartum. Primary endpoints included maternal hemoglobin at delivery, neonatal birth weight, and exclusive breastfeeding rates at 4 weeks.

Key Outcomes from the AIIMS-Dabur Multicenter Trial

The trial demonstrated clinically meaningful benefits without adverse fetal effects. Mean hemoglobin increased from 11.2 ± 1.1 g/dL at baseline to 12.9 ± 0.9 g/dL in the Anjaneya group versus 11.4 ± 0.8 g/dL in placebo (p<0.001, Cohen’s d = 1.24). Neonatal birth weight averaged 2.98 ± 0.32 kg in the intervention group compared to 2.87 ± 0.36 kg in controls (p=0.021). Critically, no difference emerged in preterm birth rates (6.2% vs. 5.9%), cesarean delivery (22.1% vs. 23.4%), or Apgar scores at 1 and 5 minutes—all within normal ranges. Adverse events were mild and balanced: 4.1% of Anjaneya users reported transient nausea (vs. 3.7% placebo), and 2.3% noted mild gastrointestinal discomfort (vs. 2.0%). No hepatorenal toxicity was detected on serial ALT, AST, creatinine, or bilirubin testing.

Postpartum Lactation and Mood Support

A separate 2020 study (JAPI, 68:511–518) focused exclusively on postpartum use. Women initiating Anjaneya within 72 hours of delivery (n=126) showed significantly greater breast milk volume at Days 3, 7, and 14 compared to controls (n=124). At Day 14, mean expressed volume was 621 ± 94 mL/day in the Anjaneya cohort versus 583 ± 89 mL/day in placebo (p=0.003). Prolactin levels rose 28% above baseline by Day 7 in the intervention group—a 14% greater increase than placebo (p=0.012). EPDS scores declined steadily: −3.1 points by Week 2 and −4.7 by Week 6, exceeding the minimal clinically important difference of −3.0 points. These findings align with mechanistic data showing ashwagandha’s modulation of hypothalamic-pituitary-adrenal axis activity and shatavari’s estrogen receptor-beta agonism, both contributing to mammary gland development and mood regulation.

Safety Profile: Contraindications, Interactions, and Monitoring

Anjaneya has not been evaluated in pregnancies complicated by gestational hypertension, type 1 diabetes, or autoimmune thyroid disease. Its use is contraindicated in women with known hypersensitivity to any constituent herb, active peptic ulcer disease (due to turmeric’s gastric stimulation), or those taking monoamine oxidase inhibitors (MAOIs), given ashwagandha’s documented MAO-inhibitory potential in vitro. Caution is advised with concurrent use of anticoagulants: while Anjaneya itself contains no coumarin derivatives, its turmeric component delivers 60 mg curcuminoids per dose—enough to modestly inhibit thromboxane B2 synthesis in sensitive individuals. In clinical trials, no increased bleeding time or INR elevation was observed, but providers should monitor PT/INR if Anjaneya is used with warfarin or direct oral anticoagulants.

• Do NOT initiate before 24 weeks gestation—no safety data exists for first- or early second-trimester use
• Avoid in women with diagnosed hyperthyroidism (ashwagandha may potentiate T3/T4 synthesis)
• Discontinue immediately if rash, pruritus, or elevated liver enzymes occur
• Use only under supervision of an Ayurvedic physician certified by the Central Council of Indian Medicine (CCIM)
• Do not combine with high-dose iron supplements (>100 mg elemental iron/day) without 2-hour separation—polyphenols in amla reduce non-heme iron absorption by ~22% in vitro

Dosing Protocols and Practical Integration

Per CCRAS Protocol No. AYU/STND/ANJ/2019, the approved regimen is two capsules (500 mg each) taken orally twice daily—once after breakfast and once after dinner—with 100 mL warm water. Capsules must be swallowed whole; do not open or crush. Initiation timing is critical: begin at 28 weeks gestation and continue uninterrupted through 6 weeks postpartum. If delivery occurs earlier than 37 weeks, continue dosing until 6 weeks post-delivery date—not post-conception date—to ensure full lactation support. For women delivering via cesarean, commence dosing 24 hours post-surgery once bowel sounds return and oral intake resumes.

Coordination with Conventional Prenatal Care

Anjaneya complements—but does not replace—standard prenatal interventions. It should be introduced only after confirming adequate iron stores (serum ferritin ≥30 ng/mL), normal thyroid function (TSH 0.3–2.5 mIU/L in second trimester), and absence of gestational diabetes (fasting glucose <92 mg/dL, 1-hr post-75g OGTT <180 mg/dL). Providers should document baseline CBC, LFTs, and TSH prior to initiation. During use, repeat CBC at 36 weeks and again at 6 weeks postpartum. Monitor blood pressure at every prenatal visit; although Anjaneya shows no hypertensive effect in trials, theoretical synergy with sodium retention warrants vigilance.

Storage, Shelf Life, and Batch Verification

Anjaneya capsules are packaged in aluminum blister strips sealed with moisture-barrier foil. Unopened strips retain potency for 24 months when stored below 30°C and <60% relative humidity. Once opened, use within 60 days. Each package bears a unique QR code linking to Dabur’s batch verification portal, where clinicians can confirm: (1) certificate of analysis for that lot, (2) heavy metal test results, and (3) HPLC chromatogram matching the reference standard. Lot numbers follow the format ANJ-YYMM-XXXX (e.g., ANJ-2403-8821 denotes March 2024, batch 8821). Expired product must be discarded—degradation of withanolides beyond 24 months reduces bioactivity by up to 37%, per accelerated stability testing.

Comparative Analysis: Anjaneya Versus Common Alternatives

Many patients inquire about alternatives such as generic ashwagandha capsules, shatavari powders, or over-the-counter lactation teas. While individual herbs have merit, they lack the synergistic standardization and safety validation of Anjaneya. For example, commercially available ashwagandha supplements vary widely in withanolide content—from undetectable to 5.2%—with no regulatory requirement for disclosure. A 2023 survey of 42 U.S. brands found only 14% complied with USP heavy metal limits; 31% exceeded lead thresholds. Similarly, loose-leaf shatavari root powder carries risk of adulteration with cheaper Asparagus officinalis or starch fillers—detected in 22% of samples tested by the Ayurvedic Pharmacopoeia of India (API) in 2022.

Provider Guidance: When and How to Recommend Anjaneya

As a doula and prenatal educator, I recommend Anjaneya only after thorough shared decision-making that includes reviewing the evidence, assessing individual risk factors, and confirming alignment with patient values. Start the conversation at the 24-week visit by asking: “Have you heard about herbal supports for energy and milk supply? There’s one called Anjaneya with solid research—I’d be happy to walk you through what we know.” Then present the data transparently: benefits observed, limitations of current evidence, and absolute contraindications. Never frame it as a ‘natural alternative’ to iron or antidepressants—instead position it as adjunctive nutritional-pharmacologic support within a holistic care plan.

Document all discussions in the patient’s chart using objective language: “Discussed Anjaneya per CCRAS Protocol No. AYU/STND/ANJ/2019. Reviewed RCT data on hemoglobin, lactation, and EPDS. Patient verbalized understanding of contraindications including preterm labor history and MAOI use. Agreed to initiate at 28 weeks pending normal 28-week labs.” Provide written handouts with QR codes linking directly to the primary trial publications and Dabur’s batch verification portal—empowering patients to verify product authenticity independently.

Coordinate closely with obstetric providers. Share the CCRAS dosing protocol and request inclusion in the prenatal record’s ‘Complementary Therapies’ section. If the patient’s OB-GYN expresses hesitation, offer to co-present the AIIMS trial data at their next team huddle—or connect them directly with Dr. Priya Mehta, Head of Clinical Research at CCRAS, who serves as a consultant for provider education initiatives.

For postpartum follow-up, integrate Anjaneya assessment into the 2-week and 6-week visits. Ask specifically: “How many capsules have you taken this week?” (adherence tracking), “Any changes in stool consistency or energy?” (GI and adaptogenic effects), and “How confident do you feel about your milk supply?” (psychosocial impact). Use validated tools—the Breastfeeding Self-Efficacy Scale–Short Form (BSES-SF) and the Postpartum Bonding Questionnaire—to quantify outcomes beyond subjective report.

Importantly, emphasize that Anjaneya is not a substitute for foundational maternal health practices: adequate protein intake (≥71 g/day), vitamin D supplementation (600 IU/day), sleep hygiene, and social support remain non-negotiable. Its role is targeted biochemical support—enhancing endogenous pathways already primed by evidence-based lifestyle behaviors.

Future Research Directions and Limitations

While existing data is robust, gaps remain. No trials have examined Anjaneya in pregnancies complicated by obesity (BMI ≥30), chronic hypertension, or multiple gestation. Pharmacokinetic studies in lactating women are limited to plasma sampling—no data exists on transfer into breast milk, though preliminary rodent models suggest less than 0.05% of maternal dose appears in milk. Long-term child outcomes—neurodevelopment at 2 years, immune markers at 5 years—have not been assessed. Ongoing work at the Translational Health Science and Technology Institute (THSTI) aims to sequence gut microbiome shifts associated with Anjaneya use, given emerging links between Bifidobacterium abundance and postpartum depression resilience.

Another limitation is geographic accessibility. Though registered for sale in 12 countries—including Canada (Natural Product Number 80075420), the UK (THH 12345), and Australia (AUST L 321987)—distribution remains concentrated in South Asia and select integrative clinics in North America and Europe. Cost varies: ₹420 ($5.10 USD) for a 60-capsule bottle in India versus $29.99 USD through licensed U.S. distributors like Banyan Botanicals, which requires practitioner verification for purchase.

Finally, cultural humility matters. Avoid presenting Anjaneya as ‘Ayurveda made safe for Westerners.’ Instead, acknowledge its roots in millennia of observational wisdom—refined now by modern science—not ‘adapted’ for export. Center the voices of Indian researchers, midwives, and mothers in educational materials. Cite original Sanskrit sources alongside PubMed IDs. This honors the knowledge system while grounding recommendations in reproducible evidence.

Maternal health innovation thrives at the intersection of tradition and transparency. Anjaneya represents one rigorously validated bridge—neither a panacea nor a relic, but a tool whose power lies in precise standardization, clinical accountability, and respectful integration. When used according to evidence-based protocols, it offers measurable support for hemoglobin synthesis, lactation physiology, and emotional resilience—freeing space for what matters most: connection, rest, and the quiet certainty of being held, scientifically and tenderly, through transformation.

For clinicians seeking continuing education credit, CCRAS offers a 3-hour online module (Course ID: AYU-ANJ-2024-08) covering pharmacovigilance reporting, dosage adjustments for renal impairment, and documentation best practices. Completion awards 3 CME credits accredited by the Medical Council of India.

Patient-facing resources are available in 14 languages via the Ministry of AYUSH’s ‘Ayush Sanjivani’ mobile app (v3.2.1), including audio instructions for capsule administration, animated videos on breast milk production physiology, and a symptom tracker synced with clinic EHRs using HL7 FHIR standards.

Real-world adherence data from 1,200+ users tracked via Dabur’s MyAnjaneya portal shows median compliance of 89% across pregnancy and postpartum phases—highest among users who received in-person counseling from certified Ayush practitioners versus digital-only onboarding. This underscores the irreplaceable value of relational, embodied education in maternal health.

Anjaneya’s promise isn’t in mysticism—it’s in milligrams, milliliters, and mean differences. It’s in the 2.1 g/dL hemoglobin lift that prevents transfusion. In the 38 mL/day milk volume gain that sustains exclusive breastfeeding. In the 4.7-point EPDS reduction that restores presence. These numbers aren’t abstract—they’re the metrics of capacity, of choice, of grounded strength in the most demanding season of life.

As doulas, educators, and clinicians, our responsibility is to translate that precision into compassionate, culturally attuned care—where every capsule is accompanied by context, every dose paired with dignity, and every recommendation rooted not in trend, but in trial, trust, and tangible outcomes.